167 related articles for article (PubMed ID: 17890456)
1. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).
Sieniawski M; Reineke T; Nogova L; Josting A; Pfistner B; Diehl V; Engert A
Blood; 2008 Jan; 111(1):71-6. PubMed ID: 17890456
[TBL] [Abstract][Full Text] [Related]
2. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.
Sieniawski M; Reineke T; Josting A; Nogova L; Behringer K; Halbsguth T; Fuchs M; Diehl V; Engert A
Ann Oncol; 2008 Oct; 19(10):1795-801. PubMed ID: 18544558
[TBL] [Abstract][Full Text] [Related]
3. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
[TBL] [Abstract][Full Text] [Related]
4. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
5. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials.
Behringer K; Mueller H; Goergen H; Thielen I; Eibl AD; Stumpf V; Wessels C; Wiehlpütz M; Rosenbrock J; Halbsguth T; Reiners KS; Schober T; Renno JH; von Wolff M; van der Ven K; Kuehr M; Fuchs M; Diehl V; Engert A; Borchmann P
J Clin Oncol; 2013 Jan; 31(2):231-9. PubMed ID: 23150709
[TBL] [Abstract][Full Text] [Related]
6. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
Borchmann P; Haverkamp H; Diehl V; Cerny T; Markova J; Ho AD; Eich HT; Mueller-Hermelink HK; Kanz L; Greil R; Rank A; Paulus U; Smardova L; Huber C; Dörken B; Nerl C; Krause SW; Mueller RP; Fuchs M; Engert A
J Clin Oncol; 2011 Nov; 29(32):4234-42. PubMed ID: 21990399
[TBL] [Abstract][Full Text] [Related]
7. ABVD and BEACOPP regimens' effects on fertility in young males with Hodgkin lymphoma.
Amin MSA; Brunckhorst O; Scott C; Wrench D; Gleeson M; Kazmi M; Ahmed K
Clin Transl Oncol; 2021 Jun; 23(6):1067-1077. PubMed ID: 32944834
[TBL] [Abstract][Full Text] [Related]
8. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).
Wannesson L; Bargetzi M; Cairoli A; Cerutti A; Heim D; Hess U; Lerch E; Pabst T; Renner C; Samaras P; Zucca E
Leuk Lymphoma; 2013 Jan; 54(1):36-40. PubMed ID: 22702653
[TBL] [Abstract][Full Text] [Related]
9. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).
Engel C; Loeffler M; Schmitz S; Tesch H; Diehl V
Ann Oncol; 2000 Sep; 11(9):1105-14. PubMed ID: 11061603
[TBL] [Abstract][Full Text] [Related]
10. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials.
Haverkamp H; Böll B; Eichenauer DA; Sasse S; Fuchs M; Borchmann P; Diehl V; Engert A; von Tresckow B
J Clin Oncol; 2015 Aug; 33(22):2430-6. PubMed ID: 26101245
[TBL] [Abstract][Full Text] [Related]
11. Fertility in young patients following treatment for Hodgkin's lymphoma: a single center survey.
Boltežar L; Pintarić K; Jezeršek Novaković B
J Assist Reprod Genet; 2016 Mar; 33(3):325-333. PubMed ID: 26678493
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
13. Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study.
Belada D; Štěpánková P; Sýkorová A; Žák P; Smolej L
Leuk Lymphoma; 2015 Jul; 56(7):2013-8. PubMed ID: 25330440
[TBL] [Abstract][Full Text] [Related]
14. Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group.
Wongso D; Fuchs M; Plütschow A; Klimm B; Sasse S; Hertenstein B; Maschmeyer G; Vieler T; Dührsen U; Lindemann W; Aulitzky W; Diehl V; Borchmann P; Engert A
J Clin Oncol; 2013 Aug; 31(22):2819-24. PubMed ID: 23796987
[TBL] [Abstract][Full Text] [Related]
15. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
16. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group.
Behringer K; Wildt L; Mueller H; Mattle V; Ganitis P; van den Hoonaard B; Ott HW; Hofer S; Pluetschow A; Diehl V; Engert A; Borchmann P;
Ann Oncol; 2010 Oct; 21(10):2052-2060. PubMed ID: 20305034
[TBL] [Abstract][Full Text] [Related]
17. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
18. Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis.
Fosså A; Fiskvik IH; Kolstad A; Lauritzsen GF; Aurlien E; Blystad AK; Hole KH; Ikonomou IM; Holte H
Ann Oncol; 2012 May; 23(5):1254-1259. PubMed ID: 21926399
[TBL] [Abstract][Full Text] [Related]
19. Which Hodgkin's patients in the Unites States should be treated with BEACOPP?
Cheson BD
Curr Hematol Malig Rep; 2014 Sep; 9(3):222-6. PubMed ID: 24879421
[TBL] [Abstract][Full Text] [Related]
20. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group.
Eichenauer DA; Thielen I; Haverkamp H; Franklin J; Behringer K; Halbsguth T; Klimm B; Diehl V; Sasse S; Rothe A; Fuchs M; Böll B; von Tresckow B; Borchmann P; Engert A
Blood; 2014 Mar; 123(11):1658-64. PubMed ID: 24478403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
